AACR StoriesThe Faces & Voices Behind the Science

Decades of pioneering research led to a first-of-its-kind FDA approval for a new type of immunotherapy—tumor-infiltrating lymphocyte (TIL) therapy.

Preventing cancer and identifying malignancies at the earliest, most treatable stages are key areas of focus for the American Association for Cancer Research (AACR) and its members.

Using funding from the AACR, early-career investigator Marco Ruella, MD, found a way to improve immunotherapy for B-cell acute lymphoblastic leukemia.